Translation News and Research

RSS

HealthPlus of Michigan partners with Edifecs to achieve HIPAA 5010 compliance

Edifecs, Inc., a leading provider of healthcare software solutions specializing in Healthcare Channel Modernization for HIPAA 5010 and ICD-10, announced today that HealthPlus of Michigan has selected Edifecs solutions to accelerate their efforts to meet the upcoming HIPAA 5010 compliance mandate. HealthPlus, a nonprofit health benefits company serving more than 200,000 people throughout the state of Michigan, will use Edifecs SpecBuilder and XEngine products for mapping and translation of inbound and outbound HIPAA 5010 transactions.

13 Sep 2010

3M Health Information Systems releases ICD-10 Code Translation Tool

3M Health Information Systems, an international leader in ICD-9 and ICD-10 coding and clinical terminology management, has released the 3M ICD-10 Code Translation Tool, now fully integrated with 3M's medical vocabulary server, the 3M Healthcare Data Dictionary, to provide a single source solution for translating and converting ICD-9 based applications to ICD-10.

13 Sep 2010

Researchers elucidate Qua1 spatial structure region of Sam68 protein

Using NMR spectroscopy, Professor Michael Sattler and his team elucidated the spatial structure of the Qua1 region of Sam68, which is responsible for the dimerization of the protein. In collaboration with the research group of Professor Ruth Brack-Werner of the Institute of Virology, the authors showed that this region is essential for the biological function of Sam68.

13 Sep 2010

AACN announces Impact Research Grant to address gaps in clinical research

The American Association of Critical-Care Nurses announces the first $50,000 AACN Impact Research Grant to support clinical inquiry and drive change in high acuity and critical care nursing practice.

13 Sep 2010

Structure of key protein for cellular signal transduction elucidated

Scientists of the Institute of Structural Biology of Helmholtz Zentrum München and the Technische Universität München have succeeded in elucidating the structure of an important region of the Sam68 protein. Sam68 is a key protein for cellular signal transduction. The Journal of Biological Chemistry has selected the report of these research findings as one of two "papers of the week" for its September 10, 2010 issue and has chosen the structural model as cover image.

10 Sep 2010

GE Healthcare to showcase molecular imaging portfolio at WMIC

Reinforcing its commitment to researchers and clinicians, GE Healthcare, a unit of General Electric Company is showcasing a comprehensive molecular imaging portfolio—encompassing tracer development, pre-clinical imaging and highly advanced imaging equipment— to provide insight into the origins of disease, at the World Molecular Imaging Congress (WMIC), Booth #212, September 8 through 11 in Kyoto, Japan.

10 Sep 2010

Translational Research issue focuses field of stem cell research, therapy

The use of stem cells for research and their possible application in the treatment of disease are hotly debated topics. In a special issue of Translational Research published this month an international group of medical experts presents an in-depth and balanced view of the rapidly evolving field of stem cell research and considers the potential of harnessing stem cells for therapy of human diseases including cardiovascular diseases, renal failure, neurologic disorders, gastrointestinal diseases, pulmonary diseases, neoplastic diseases, and type 1 diabetes mellitus.

10 Sep 2010

Highlights of 23rd Congress of European College of Neuropsychopharmacology 2010

More than 7,000 psychiatrists, neurologists, psychologists and neuroscience researchers from all over the world met at the 23rd Congress of the European College of Neuropsychopharmacology (ECNP) from 28 August to 1 September 2010 in Amsterdam.

10 Sep 2010

PLX4032 trial shows high degree of selectivity to achieve tumor shrinkage

Plexxikon today announced publication of key data in this week's edition of Nature demonstrating that the high degree of selectivity of PLX4032 (RG7204) enables substantial RAF/MEK/ERK pathway inhibition, which may be necessary to achieve significant tumor shrinkage and clinical response in patients with BRAF mutant melanoma.

8 Sep 2010

Researchers unveil prototype model of first implantable artificial kidney

UCSF researchers today unveiled a prototype model of the first implantable artificial kidney, in a development that one day could eliminate the need for dialysis.

3 Sep 2010

TGen researchers use RNAi-based screening to study Ewing's sarcoma

The first study of Ewing's sarcoma that screened hundreds of genes based on how they affect cell growth has identified two potential anti-cancer drug targets, according to a scientific paper by the Translational Genomics Research Institute published this month in the journal Molecular Cancer.

2 Sep 2010

Cell Therapy Foundation analysis calls for funding in medical research

Some of the most promising medical research conducted to treat diseases of the brain, heart, and circulatory system is moving too slowly to help millions of patients, according to the Cell Therapy Foundation, which advocates the use of adult stem cells to dramatically impact and improve the condition of patients who suffer from a variety of conditions.

31 Aug 2010

Cognizant Communication launches 'Cell Medicine' open access journal

A new and unique journal on cell transplantation aimed at helping translate laboratory findings into clinical applications is being launched by Cognizant Communication Corporation as a companion journal to Cell Transplantation. Cell Medicine, an online-only, open access journal, publishes research papers that promise to have direct clinical relevance. The journal is freely accessible at: http://www.ingentaconnect.com/content/cog/cm.

30 Aug 2010

Preclinical studies of BIND-014 to be presented at ACS National Meeting

BIND Biosciences announced today the presentation of its Medicinal Nanoengineering platform at the ACS National Meeting, including results from preclinical studies on its lead nanomedicine drug , BIND-014, scheduled to enter clinical trials later this year. BIND-014 is a targeted, polymeric nanoparticle containing the cytotoxic agent, docetaxel, which is approved in major cancer indications, including breast, prostate and lung.

23 Aug 2010

HHS Secretary releases review of new federal approach to medical countermeasures

U.S. Department of Health and Human Services Secretary Kathleen Sebelius today released an examination of the federal government's system to produce medications, vaccines, equipment and supplies needed for a health emergency, known as medical countermeasures. The Public Health Emergency Medical Countermeasure Enterprise Review: Transforming the Enterprise to Meet Long Range National Needs reviews the process and makes recommendations for a better approach.

21 Aug 2010

Exiqon reports 2010 second quarter revenue increases 27%

Exiqon today announced results for the first six months of 2010 ending 30 June 2010. Revenue for the first six months increased 27% to a record DKK 44.8 million.

19 Aug 2010

MD Anderson Cancer Center receives $20 million to advance research on targeted therapies

Dallas businessman and philanthropist H. Ross Perot has donated $20 million to The University of Texas MD Anderson Cancer Center for research to advance and design novel targeted therapies.

19 Aug 2010

AACR opens nominations for awards recognizing excellence in cancer research

The American Association for Cancer Research is currently accepting nominations for awards recognizing excellence in cancer research, to be presented at the 102nd AACR Annual Meeting 2011, held in Orlando, Fla., from April 2 to 6.

18 Aug 2010

Advanced Cell Technology to obtain patent for cellular reprogramming, generation of iPS cells

Advanced Cell Technology, Inc. announced today that it is positioned to obtain significant patents relating to cellular reprogramming and the generation of induced pluripotent stem (iPS) cells. iPS cells are similar to embryonic stem (ES) cells, except they are generated from adult cells such as skin using certain reprogramming factors, without the controversial use of embryos. Although human iPS cells were first produced in 2007, ACT has been working on inducing pluripotency, with positive results, for more than a decade. The Company's efforts go back to the 1990s, providing (through existing patent filings and continuations) some of the earliest priority dates in the field.

18 Aug 2010

Study finds abnormal expression of miRNAs can contribute to human diseases

Researchers at Tufts University School of Medicine and Tufts Medical Center have identified an RNA sequence that promotes increased numbers of specific microRNAs (miRNAs), molecules that regulate cell growth, development, and stress response. The discovery helps researchers understand the links between miRNA expression and disease, including heart disease and cancer. The findings are published in the August 13 issue of Molecular Cell.

17 Aug 2010